RWE

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

Retrieved on: 
Giovedì, Maggio 9, 2024
FDA, Fast Track, Research, Rett syndrome, Trial of the century, Partnership, Doctor of Philosophy, Conference call, CNS, Procedure, Frontotemporal dementia, EDGAR, Food, Orphan drug, European Medicines Agency, Brain, RWE, MECP2, Drug development, RNA-Seq, Conference, Publication, Pharmacokinetics, U.S. FDA, Marketing authorisation, DSM-IV codes, Patent, Real, RNA, Human, Therapy, Treatment, EMA, Alzheimer's disease, Central nervous system, Clinical trial, Medicine, Marketing, ADAS, Centralisation, Pharmacology, European, Patient, Expanded access, Caregiver, Webcast, Interim, Bank statement, Pharmaceutical industry

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended March 31, 2024.

Key Points: 
  • Parkinson’s disease: Initiation of ANAVEX®2-73 imaging-focused trial and Phase 2b/3 6 month trial is expected in the second half of 2024.
  • General and administrative expenses for the quarter of $2.8 million compared to $2.9 million for the comparable quarter of fiscal 2023.
  • Research and development expenses for the quarter of $9.7 million compared to $11.3 million for the comparable quarter of fiscal 2023.
  • The financial information for the fiscal quarter ended March 31, 2024, should be read in conjunction with the Company’s condensed consolidated interim financial statements, which will appear on EDGAR, www.sec.gov and will be available on the Anavex website at www.anavex.com .

Komodo Health & Partners Present 33 Real-World Evidence Research Studies at ISPOR 2024

Retrieved on: 
Lunedì, Maggio 6, 2024
Technology, Health, Venture Capital, Professional Services, Artificial Intelligence, Oncology, Other Science, Mental Health, Research, Software, Health Technology, Science, COVID-19, Clinical Trials, Komodo, University of Washington, Lennox–Gastaut syndrome, FDA, Public, University, Target, International Society, RWE, Pregnancy, Policy, AI, Prevalence, Colorectal cancer, Myriad Genetics, LGS, Chronic inflammatory demyelinating polyneuropathy, Neutropenia, CRC, Conference, Workflow, REMS, Genetics, Schizophrenia, Takeda Pharmaceutical Company, Mental health, Neurology, RWD, MPH, Patient, Hypertension, Epilepsy, Gestational age, Standard of care, Stillbirth, Pharmacoeconomics, ZS, Merck, ZS Associates, Breast cancer, Mitigation, Pharmaceutical industry

Komodo Health today announced the publication of 33 new health economics and outcomes research (HEOR) studies using its Healthcare Map and AI-powered technology platform.

Key Points: 
  • Komodo Health today announced the publication of 33 new health economics and outcomes research (HEOR) studies using its Healthcare Map and AI-powered technology platform.
  • The studies, to be featured at the 2024 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Global Conference, shed light on important disease trends spanning women’s health, oncology, mental health, hypertension, neurology, and more.
  • Komodo Health researchers studied the differences in patient outcomes for pregnant women who continued or discontinued the use of antidepressants during pregnancy.
  • Komodo Health researchers analyzed whether the COVID-19 pandemic exacerbated inequities in breast cancer care through its impact on breast cancer staging and HCRU.

OM1 Launches Three New Products Powered by Patented AI Platform to Expedite Delivery of Personalized Medicine

Retrieved on: 
Lunedì, Maggio 6, 2024
Technology, Research, Clinical Trials, Health Technology, Health Insurance, Health, Pharmaceutical, Science, Artificial Intelligence, Real-World Evidence, RWE, Lyra, HCP, OM1, Risk, AI, Population health, Phenom, Disease, Orion, Patient, Medicine, Diagnosis, Standard of care, Clinical trial

OM1 introduces three new products: OM1 Orion, OM1 Lyra, and OM1 Polaris powered by PhenOMTM – an artificial intelligence-powered digital phenotyping platform for personalized medicine and clinical research.

Key Points: 
  • OM1 introduces three new products: OM1 Orion, OM1 Lyra, and OM1 Polaris powered by PhenOMTM – an artificial intelligence-powered digital phenotyping platform for personalized medicine and clinical research.
  • Leveraging high-volume deep clinical data, OM1 Orion delivers a multi-layered 360-degree view of disease progression and burden for patient sub-populations.
  • OM1 Orion provides a substantially more accurate picture of the patient journey while significantly reducing research timelines and associated costs.
  • To learn more about OM1’s real-world data and patented AI technology, please email [email protected] .

Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons

Retrieved on: 
Giovedì, Maggio 2, 2024
Outcomes research, RWE, Real, WHO, Influenza, World Health Organization, Influenza vaccine, ASX, CSL, Season, Vaccine

A real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID) examined three consecutive U.S. flu seasons in the United States.

Key Points: 
  • A real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID) examined three consecutive U.S. flu seasons in the United States.
  • "With data collected over three consecutive seasons, our study suggests higher vaccine effectiveness of cell-based quadrivalent influenza vaccines compared with standard egg-based influenza vaccines."
  • These data build on the growing evidence of real-world data that shows the benefits of our cell-based influenza vaccine," said Gregg Sylvester, Chief Health Officer and Head of Medical Affairs, CSL Seqirus.
  • "At CSL Seqirus, we're continually driving vaccine technology forward, in order to improve effectiveness and help keep communities healthy."

Deep 6 AI and Magnolia Market Access Partner to Accelerate Real-World Evidence (RWE) Projects for Life Sciences Companies and Healthcare Organizations

Retrieved on: 
Giovedì, Maggio 2, 2024
RWE, Ecosystem, Publication, Policy, EMR, Partnership, Magnolia, Research, Pathology, Artificial intelligence, Radiology, Patient, RWD, Magnolia Market, Clinical trial, Medical device

PASADENA, Calif., May 2, 2024 /PRNewswire/ -- Deep 6 AI, the leader in AI-powered patient recruitment and real-world data (RWD), together with Magnolia Market Access, a provider of tailored RWD insights and strategies for market access, health economics and outcomes research (HEOR), and healthcare policy, today announced a partnership to accelerate stakeholder decision-making across the pharmaceutical, biologic, and medical device product lifecycle. The combined RWE generation solution uses AI to develop fit-for-purpose, analysis-ready clinical data sets from electronic medical record (EMR) data months faster than traditional approaches.

Key Points: 
  • Typically, it can take life sciences companies a year or more to contract with healthcare organizations to gain access to EMR data.
  • "The speed and precision with which we generate clinical insights is paramount to our life sciences customers' success," said Amanda Forys, Managing Partner at Magnolia Market Access.
  • Life sciences companies can meet Deep 6 AI and Magnolia Market Access at ISPOR 2024 , May 5 to 8 in Atlanta, Georgia.
  • Contact Deep 6 AI or Magnolia Market Access to schedule a meeting.

Petauri™ Further Expands with Accomplished Evidence and Strategy Executives

Retrieved on: 
Giovedì, Maggio 2, 2024
Public policy, RWE, Public health, Partnership, Translation, Patient, Avalere Health, Senior advisor, Amgen

NASHVILLE, Tenn., May 2, 2024 /PRNewswire/ -- Petauri, a leading purpose-built pharmaceutical services platform, announced today the addition of Nicole Lodowski and Bob Nordyke to lead a team dedicated to evidence generation and value strategy across the product lifecycle, from early pipeline evidence planning through post-launch evidence generation.

Key Points: 
  • Amid escalating challenges in the biopharmaceutical industry, the demand for and complexity of evidence to support access to essential therapies continue to rise.
  • With an innovative and strategy-forward approach, they will partner with top biopharmaceutical companies to transcend traditional boundaries in evidence generation and drive meaningful patient access and impact.
  • Key offerings include evidence strategy and planning, real-world evidence (RWE) generation and analysis, modeling, simulation, and evidence synthesis.
  • I'm thrilled to have them––and the incredible team they are leading––to build out another area of critical need within Petauri."

EQS-News: Tosyalı Wins the “Rhine Water Pipeline (RWTL)” Tender, One of Germany’s Most Important Environmental Transformation Projects

Retrieved on: 
Venerdì, Maggio 3, 2024
Rhine, RWE, Water

Tosyalı Wins the “Rhine Water Pipeline (RWTL)” Tender, One of Germany’s Most Important Environmental Transformation Projects

Key Points: 
  • Tosyalı Wins the “Rhine Water Pipeline (RWTL)” Tender, One of Germany’s Most Important Environmental Transformation Projects
    The issuer is solely responsible for the content of this announcement.
  • Tosçelik Spiral Boru, one of the successful companies of Tosyalı, Türkiye's global steel producer and Europe's largest pipe manufacturer, has won the "Rhine Water Pipeline" (RWTL) tender.
  • Cologne - The Rhine Water Pipeline (RWTL)  is one of Germany's most important environmental transformation projects, which aims to bring water from the Rhine River to fill disused opencast mines.
  • Tosyalı and RWE Power signed a contract at RWE’s convention centre, Paffendorf Castle, near Cologne.

Osmind Announces Collaboration with the American Psychiatric Association to Advance Quality Psychiatric Care and Accelerate Research

Retrieved on: 
Giovedì, Maggio 2, 2024
Software, Practice Management, General Health, Health, Mental Health, Data Management, Health Technology, Technology, APA, Education, RWE, American Psychiatric Association, Psychiatry, Private practice, EHR, MD, Collection, Automation, Patient, MBC, Medicine, Nursing

Today, Osmind , the leading psychiatric treatment and research platform, announced an innovative collaboration with the American Psychiatric Association (APA) to improve the adoption of measurement-based care (MBC) and precision treatment in psychiatry.

Key Points: 
  • Today, Osmind , the leading psychiatric treatment and research platform, announced an innovative collaboration with the American Psychiatric Association (APA) to improve the adoption of measurement-based care (MBC) and precision treatment in psychiatry.
  • This collaboration between Osmind and APA’s PsychPRO registry intends to broaden access to personalized care, improve patient outcomes, generate robust real-world evidence (RWE) and accelerate psychiatry’s evolution to precision medicine.
  • PsychPRO registry is a clinical data registry that enables the collection and analysis of clinical data to advance quality improvement efforts and accelerate research for the psychiatric community.
  • Through this collaboration, Osmind is enabling independent practices to contribute to the evolution of the field and elevate their own evidence-based practices.

Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study

Retrieved on: 
Mercoledì, Aprile 10, 2024
RWE, Inflammation, DSM-IV codes, Osteoarthritis, TSX, Arthritis, Patient, Rheumatoid arthritis, MUSCULAR, Cannabidiol, Fibromyalgia, CBG, Overalls

The RWE study revealed a meaningful improvement in overall Musculoskeletal Health Questionnaire scores (p

Key Points: 
  • The RWE study revealed a meaningful improvement in overall Musculoskeletal Health Questionnaire scores (p
  • The RWE study participants with an average age of 58 ± 15 (64% women) all presented with symptoms of chronic pain.
  • Prior to initiation of the study, study participants reported they were taking an average of ten medications including NSAIDs, opioids, antidepressants, or skeletal muscle relaxants.
  • Each RWE study participant was assigned a common treatment plan of a combination of a CBD oil (83.3%) or balance oil (16.7%) with the RHO Phyto CBG Transdermal Gel.

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

Retrieved on: 
Giovedì, Aprile 25, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Cancer, RWE, EDT, Cancer Moonshot, Lung cancer, Hope, Nivolumab, American Urological Association, Second, Pembrolizumab, Survival, Immunotherapy, American Cancer Society, Webcast, BCG, Disease, Patient, Medicine, AUA, Multimedia, Death, NK, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240424428572/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240424428572/en/
    In NSCLC patients who relapsed or were refractory to checkpoint inhibitors, ANKTIVA was administered together with the same checkpoint inhibitor.
  • The addition of ANKTIVA resulted in the rescue of the checkpoint therapy efficacy, with significant prolongation of overall survival.
  • This prolongation of survival in NSCLC following checkpoint failure is consistent with ImmunityBio’s findings of durable complete responses following BCG failure in NMIBC.
  • According to the American Cancer Society, lung cancer is the second most common cancer in the U.S.